Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

In his first town hall since voting in favor of Donald Trump’s “big, beautiful bill,” Nebraska Representative Mike Flood had ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Texas state Representative Mitch Little confessed the simple reality of his party’s sudden push for a new congressional map.

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...

After Loomer targeted surgeon general nominee and Kennedy ally Casey Means, Means’s brother, Calley, suggested that Loomer’s ...

The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.

Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...

I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...